Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Jan 25, 2023 1:02pm
246 Views
Post# 35245573

RE:RE:Excellent news! Out first official exposure to ASCO world

RE:RE:Excellent news! Out first official exposure to ASCO world

There are rules for abstracts and presentation.  It's not as one wants!


The upcoming presentation should have the same type of data than the Ph. 1b data:

https://www.sciencedirect.com/science/article/pii/S2666168322005900


By the way, late abstract deadline for April 29 congress is Feb. 13.

For the June 2-6 ASCO conference, that Feb. 12:

June 2-6, 2023 • McCormick Place • Chicago, IL & Online
 

Abstract Submission

Hero Text

 



The 2023 Annual Meeting is now accepting abstract submissions until February 14. View the Call for Abstracts booklet for detailed information on submitting an abstract including submission categories, guidelines, and policies.

For our Feb. ASCO one, that Dec. 13:
 

Late-Breaking Data Submission Guidelines

Page Description
 
 
 
Body

The ASCO late-breaking data policy allows for the submission of late-breaking data only for:

  • Randomized phase II and III trials for which no preliminary data are available at the time of the abstract submission deadline (October 11, 2022);

OR

  • Original research studies that highlight novel and high-impact research with practice-changing implications

The initial abstract must be submitted by the October 11, 2022 deadline in a placeholder (shell) abstract submission. During submission, you will be required to enter all authors, the Background and Methods sections, and provide the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods.

The policy is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the abstract submission deadline. Additionally, late-breaking submissions cannot be a revision of an abstract submitted during the regular submission process. 

 

Guidelines for Consideration

 
Body

For an abstract to be considered for late-breaking data submissions status, the first author must:

  • Submit an abstract, completing all steps in the submitter with the exception of the Results and Conclusions sections, by the abstract submission deadline (October 11, 2022)
  • Adhere to the confidentiality policy
  • Describe the type of data that will be submitted by the late-breaking data submission deadline, indicating the primary clinical endpoint for analysis, planned statistical plan for analysis, and date of planned analysis. (For example, “Survival data for the two treatment arms will be compared using a log-rank test.”) In general, ASCO discourages reporting of interim analysis results, unless approved by the study’s Data and Safety Monitoring Committee.

The final, updated late-breaking data should be submitted by December 13, 2022, at 12:00 PM (Noon) EST -- the late-breaking submission deadline. If an updated abstract with data and analyses is not submitted, ASCO will follow up with the authors directly to determine appropriate next steps.

<< Previous
Bullboard Posts
Next >>